Adult IDH wild-type lower-grade gliomas should be further stratified

2016, The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1

2015, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012, Neuro Oncol, 17, iv1, 10.1093/neuonc/nov189

2016, High-grade glioma management and response assessment-recent advances and current challenges, Curr Oncol, 23, e383, 10.3747/co.23.3082

2016, Maximizing safe resection of low- and high-grade glioma, J Neurooncol, 130, 269, 10.1007/s11060-016-2110-4

2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710

2015, Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors, N Engl J Med, 372, 2499, 10.1056/NEJMoa1407279

2010, Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis, Acta Neuropathol, 120, 719, 10.1007/s00401-010-0777-8

2015, Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities, Acta Neuropathol, 130, 407, 10.1007/s00401-015-1454-8

2015, TERT promoter mutations contribute to subset prognostication of lower-grade gliomas, Mod Pathol, 28, 177, 10.1038/modpathol.2014.94

2015, Combination genetic signature stratifies lower-grade gliomas better than histological grade, Oncotarget, 6, 20885, 10.18632/oncotarget.4928

2016, Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic, Oncotarget, 7, 64615, 10.18632/oncotarget.11378

2011, Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade, Brain Pathol, 21, 57, 10.1111/j.1750-3639.2010.00453.x

2015, Biomarker-based prognostic stratification of young adult glioblastoma, Oncotarget, 7, 5030

2015, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas, N Engl J Med, 372, 2481, 10.1056/NEJMoa1402121

TCGA Research Network, 2016, Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma, Cell, 164, 550, 10.1016/j.cell.2015.12.028

1992, Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours, Br J Cancer, 66, 373, 10.1038/bjc.1992.273

1992, Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis, J Neuropathol Exp Neurol, 51, 84, 10.1097/00005072-199201000-00010

2014, Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes, Neurology, 83, 1200, 10.1212/WNL.0000000000000814

2015, Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes, Neurology, 84, 2007, 10.1212/WNL.0000000000001625

2012, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, 483, 479, 10.1038/nature10866

2013, IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker, Br J Neurosurg, 27, 442, 10.3109/02688697.2013.771139

2015, DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status, Acta Neuropathol Commun, 3, 34, 10.1186/s40478-015-0213-3

2010, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2, Neurology, 74, 1886, 10.1212/WNL.0b013e3181e1cf3a

2015, TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas, Neuro Oncol, 17, 45, 10.1093/neuonc/nou158

2000, MYB oncogene amplification in hereditary BRCA1 breast cancer, Cancer Res, 60, 5323

1997, Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene, Cancer Res, 57, 3135

1984, Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma, Proc Natl Acad Sci U S A, 81, 4534, 10.1073/pnas.81.14.4534

1990, The cellular myb oncogene is amplified, rearranged and activated in human glioblastoma cell lines, Cancer Lett, 52, 57, 10.1016/0304-3835(90)90077-B

1999, Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification, Cancer Res, 59, 3365

St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project, 2013, Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas, Nat Genet, 45, 602, 10.1038/ng.2611

2013, Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1, Proc Natl Acad Sci U S A, 110, 8188, 10.1073/pnas.1300252110

St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project, 2013, Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas, Nat Genet, 45, 602, 10.1038/ng.2611

2010, MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas, Acta Neuropathol, 120, 731, 10.1007/s00401-010-0763-1

2011, Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma, Acta Neuropathol, 121, 397, 10.1007/s00401-011-0802-6

2013, BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults, J Clin Oncol, 31, e233, 10.1200/JCO.2012.46.0220

2015, BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma, J Clin Oncol, 33, 1015, 10.1200/JCO.2014.58.3922

2014, Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy, BMC Cancer, 14, 258, 10.1186/1471-2407-14-258

2010, Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas, Acta Neuropathol, 120, 707, 10.1007/s00401-010-0781-z

2015, IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO, Acta Neuropathol, 129, 867, 10.1007/s00401-015-1438-8